Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02147509
Other study ID # BCL-018-SS
Secondary ID
Status Completed
Phase N/A
First received May 13, 2014
Last updated July 20, 2014
Start date March 2013
Est. completion date April 2014

Study information

Verified date July 2014
Source Wenzhou Medical University
Contact n/a
Is FDA regulated No
Health authority China: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the therapeutic effect and safety of therapeutic bandage contact lenses treating dry eye caused by Sjögren's syndrome.


Description:

Comparisons were made between Sjögren's syndrome patients with severe dry eye on the subjective and objective therapeutic effects of the overnight therapeutic bandage contact lenses at different period (i.e. before wearing, after wearing 3 weeks, after another 3 weeks with new lens and after 6 weeks without wearing ) based on the results of examinations.


Recruitment information / eligibility

Status Completed
Enrollment 64
Est. completion date April 2014
Est. primary completion date April 2014
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- Gender: male or female between 18~70 years old without wearing contact lens.

- Diagnosis and classification: all patients should have the symptoms and signs of severe dry eye (conforming to grade 3 or 4 in DEWS2007). Should have at least two positive symptoms such as dryness, foreign body sensation, burning, asthenopia, red eye or secretion. Tear film breakup time (TFBUT) shorter than 5 seconds and/or Schirmer I less than 5 mm/5 min. Corneal fluorescein staining more than 6 scores and (or) more than 3 scores of bulbar conjunctiva lissamine green liquor.

- Both eyes of all patients were preliminarily examined, the patients with single eye that meets the criterion were also investigated. Objective indicators were investigated on each eye. While the ocular surface disease index (OSDI) scores and SF-36 results were evaluated on an individual base.

- All patients should not participate in other medical tests in the past 2 weeks.

- Should either not be treated with other medicine at present, or have been treated with other medicine but had paused more than 2 weeks

Exclusion Criteria:

- Pregnant or maternity: exclude the patients who are or will be pregnant or during breast feeding.

- Other surface diseases: exclude the patients who are suspected or complicated by other obvious ocular surface diseases.

- Severe systemic diseases: exclude the patients with severe primary diseases in heart, brain blood vessel, liver, kidney, hematopoietic system and so on.

- Intraocular surgery or trauma: exclude the patients with intraocular surgery or trauma during 6 months.

- Hormone replacement therapy : exclude post-menopausal women who are treated in hormone replacement therapy.

- Lacrimal punctum: exclude the patients who have been treated with lacrimal punctum in 1 month.

- Glaucoma or high IOP: exclude the patients who have glaucoma or high intraocular pressure (IOP) sores.

- Exclude the patients who are sensitive to steroid.

- Exclude the patients who can't wear the therapeutic bandage contact lens during the clinical study.

- Immunosuppressive therapies: exclude the patients who are using systemic steroid or immunosuppressive therapies which may influent the results of the evaluation of the therapeutic effect.

- Excluding the patients who may not be suitable for the clinical examination.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
0.02% Fm, SH
Sjogren's Syndrome patients with severe dry eye
0.02% Fm, SH, 0.05% CsA
Sjogren's Syndrome patients with severe dry eye
Other:
0.02% Fm, SH, tBCL
Sjogren's Syndrome patients with severe dry eye
Drug:
0.02% Fm, SH, AS
Sjogren's Syndrome patients with severe dry eye

Locations

Country Name City State
China Eye Hospital, Wenzhou Medical College Wenzhou Zhejiang

Sponsors (1)

Lead Sponsor Collaborator
Jinyang Li

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Bulbar conjunctiva lissamine green staining Divide the bulbar conjunctiva into 3 quadrants and score each quadrant:
0 score-no stain
score-between 1 and 3 spots stained
scores-greater than or equal 4 spots stained
scores-spots stained fusion or filamentary
up to 12 weeks No
Primary C Corneal fluorescein staining Divide the corneal into 4 quadrants and score each quadrant:
0 score-no stains
score-between 1 and 3 spots stained
scores-greater than or equal 4 spots stained
scores-spots stained fusion or filamentary
up to 12 weeks Yes
Secondary Visual acuity statistical analysis by logMAR. up to 12 weeks Yes
Secondary Tear film breakup time The lower fornix was stained with fluorescein paper, after the patient blinked a couple of times, the length of time between the last blink and tear BUT was recorded in seconds using a biomicroscope with cobalt blue lightning up to 12 weeks No
Secondary Schirmer I test standard Schirmer paper (5 mm width x 35 mm length) was placed at the intersection point of the lateral and middle one-third quadrants of the lower eye lid without anesthesia,and the wetting level was recorded in mm after 5 minThe operation is completed in the same laboratory. up to 12 weeks No
Secondary quality of the life tested by The Medical Outcomes Study 36-Item Short-Form Health Survey up to 12 weeks No
Secondary Symptom of the dryness Tested by ocular surface disease index up to 12 weeks No